VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Wednesday, January 7, 2026

Stock Comparison

Boston Scientific Corporation vs Compagnie Financiere Richemont SA

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Boston Scientific Corporation

BSX · New York Stock Exchange

Market cap (USD)$141.5B
Gross margin (TTM)65.1%
Operating margin (TTM)17.3%
Net margin (TTM)14.4%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2026-01-04
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Boston Scientific Corporation's moat claims, evidence, and risks.

View BSX analysis

Compagnie Financiere Richemont SA

CFR · SIX Swiss Exchange

Market cap (USD)$100B
Gross margin (TTM)66.8%
Operating margin (TTM)21.3%
Net margin (TTM)14.8%
SectorConsumer
IndustryLuxury Goods
CountryCH
Data as of2025-12-30
Moat score
84/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Compagnie Financiere Richemont SA's moat claims, evidence, and risks.

View CFR analysis

Comparison highlights

  • Moat score gap: Compagnie Financiere Richemont SA leads (84 / 100 vs 65 / 100 for Boston Scientific Corporation).
  • Segment focus: Boston Scientific Corporation has 5 segments (49.8% in Cardiology); Compagnie Financiere Richemont SA has 3 segments (71.6% in Jewellery Maisons).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
  • Moat breadth: Boston Scientific Corporation has 6 moat types across 3 domains; Compagnie Financiere Richemont SA has 4 across 2.

Primary market context

Boston Scientific Corporation

Cardiology

Market

Cardiology devices (interventional cardiology, structural heart, electrophysiology, cardiac rhythm management and remote monitoring)

Geography

Global

Customer

Hospitals/cath labs/EP labs and specialty clinics (cardiologists, electrophysiologists)

Role

Medical device OEM / implantables + procedure devices + service-enabled monitoring

Revenue share

49.8%

Compagnie Financiere Richemont SA

Jewellery Maisons

Market

Luxury jewellery (branded fine jewellery & high jewellery)

Geography

Global

Customer

Affluent and high-net-worth consumers

Role

Brand owner, manufacturer and direct-to-client retailer

Revenue share

71.6%

Side-by-side metrics

Boston Scientific Corporation
Compagnie Financiere Richemont SA
Ticker / Exchange
BSX - New York Stock Exchange
CFR - SIX Swiss Exchange
Market cap (USD)
$141.5B
$100B
Gross margin (TTM)
65.1%
66.8%
Operating margin (TTM)
17.3%
21.3%
Net margin (TTM)
14.4%
14.8%
Sector
Healthcare
Consumer
Industry
Medical - Devices
Luxury Goods
HQ country
US
CH
Primary segment
Cardiology
Jewellery Maisons
Market structure
Oligopoly
Oligopoly
Market share
n/a
30%-55% (implied)
HHI estimate
n/a
n/a
Pricing power
Moderate
Strong
Moat score
65 / 100
84 / 100
Moat domains
Demand, Legal, Supply
Demand, Supply
Last update
2026-01-04
2025-12-30

Moat coverage

Shared moat types

Reputation ReviewsDistribution Control

Boston Scientific Corporation strengths

Installed Base ConsumablesProcurement InertiaTraining Org Change CostsRegulated Standards Pipe

Compagnie Financiere Richemont SA strengths

Brand TrustCapex Knowhow Scale

Segment mix

Boston Scientific Corporation segments

Full profile >

Endoscopy

Oligopoly

16%

Urology

Competitive

13.1%

Neuromodulation

Oligopoly

6.6%

Cardiology

Oligopoly

49.8%

Peripheral Interventions

Competitive

14.4%

Compagnie Financiere Richemont SA segments

Full profile >

Jewellery Maisons

Oligopoly

71.6%

Specialist Watchmakers

Oligopoly

15.3%

Other (Fashion & Accessories, Watchfinder, ancillary)

Competitive

13%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.